Zusammenfassung
Seit seiner Einführung als Basistherapeutikum ist der Folsäureantagonist Methotrexat (MTX) eine tragende Säule antirheumatischer Therapie. Dies hat sich auch nach Einführung der neuen, auf rekombinanten Proteinen basierenden, „Biologicals“ nicht grundlegend geändert. Trotz eindrucksvoller Fortschritte zeigt auch heute annähernd jeder zweite Patient ein nur suboptimales Ansprechen auf Antirheumatika. Eine fehlende oder insuffiziente Wirksamkeit zeigt sich insbesondere bei etwa jedem vierten Patienten unter MTX und führt oftmals zum Absetzen des Medikaments. Hinzu kommen Nachjustierungen der Pharmakotherapie infolge von Unverträglichkeiten. Vor diesem Hintergrund und unter Berücksichtigung der zunehmenden Vereinfachung der Nutzung genetischer Analysen in der medizinischen Praxis ist die Erarbeitung von Strategien zur Umsetzung individualisierter Pharmakotherapie heute zentrales Forschungsfeld. Zahlreiche Studien der letzten Jahre analysierten in diesem Zusammenhang Genpolymorphismen zellulärer Parameter, die mit Wirkung und Toxizität von MTX in Beziehung stehen. Die bislang vorliegenden Resultate belegen gleichsam Potenzial und Limitationen des wichtigen Instruments der klinischen Genpolymorphismusanalyse.
Abstract
Since its introduction as a disease-modifying drug, methotrexate (MTX), a folate antagonist, is regarded as a major pillar of anti-rheumatic pharmacotherapy. This has not been changed in the current era of biologicals based on recombinant proteins. Despite most promising therapeutic progress about half of rheumatoid arthritis patients still display insufficient response to anti-rheumatic drugs. Specifically, about one in four patients on MTX shows lack of sufficient therapeutic efficacy which may lead to drug discontinuation. In addition, adjustment of therapy may be necessary due to individual drug toxicity. In this context and in light of recent advances concerning the use of genetic analysis in clinical practice, the development of novel strategies which implement individualized pharmacotherapy has become a major issue for translational and clinical research. Accordingly, numerous studies have been performed in recent years analyzing genetic polymorphisms of cellular parameters which relate to MTX efficacy and toxicity. Data currently available demonstrate the potential and the limitations of clinical genetic polymorphism analyses.
Literatur
Braun J, Rau R (2009) An update on methotrexate. Curr Opin Rheumatol 21:216–223
Berkun Y, Levartovsky D, Rubinow A et al (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227–1231
Dervieux T, Furst d, Lein DO et al (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766–2774
Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54:3095–3103
Drozdzik M, Rudas T, Pawlik A et al (2007) Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 7:404–407
Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439):487–491
Fiehn C (2009) Methotrexate in rheumatology. Z Rheumatol 68:747–756
Fisher MC, Cronstein BN (2009) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539–545
Gervasini G (2009) Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 10:547–566
Ghodke Y, Chopra A, Joshi K, Patwardhan B (2008) Are thymidylate synthase and methylene tetrahydrofolate reductase genes linked with methotrexate response(efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? Clin Rheumatol 27:787–789
Grabar PB, Rojko S, Logar D, Dolzan V (2010) Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 69(5):931–932
Haagsma CJ, Blom HJ, van Riel PL et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58:79–84
Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770
Hider SL, Thomson W, Mack LF et al (2008) Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford) 47:1156–1159
Komar AA (2007) Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8:1075–1080
Kooloos WM, Huizinga TW, Guchelaar HJ, Wessels JA (2010) Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des 16:164–175
Kumagai K, Hiyama K, Oyama T et al (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593–600
Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356(9242):1667–1671
Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572–579
Sorich MJ, Pottier N, Pei D et al (2008) In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 5:e83
Takatori R, Takahashi KA, Tokunaga D et al (2006) ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 24:546–554
Urano W, Taniguchi A, Yamanaka T et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenomics 12:183–190
Ede AE van, Laan RF, Blom HJ et al (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27:277–292
Ede AE van, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525–2530
Warren RB, Smith RL, Campalani E et al (2008) Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128:1925–1929
Weisman MH, Furst DE, Park GS et al (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 54:607–612
Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087–1095
Wessels JA, Kooloos WM, De Jonge R et al (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830–2839
Wessels JA, van der Kooij SM, le Cessie S et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56:1765–1775
Wessels JA, Huizinga TW, Guchelaar HJ (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47:249–255
Interessenkonflikt
Keine Angaben.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mühl, H., Pfeilschifter, J. Pharmakogenetik und Pharmakogenomik von Methotrexat. Z. Rheumatol. 70, 101–107 (2011). https://doi.org/10.1007/s00393-010-0686-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-010-0686-1